Dennis T Ko1, Peter C Austin2, Jack V Tu2, Douglas S Lee2, Lingsong Yun2, David A Alter2. 1. From the Institute of Clinical Evaluative Sciences, Toronto, Ontario, Canada (D.T.K., P.C.A., J.V.T., D.S.L., L.Y., D.A.A.); Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (D.T.K., J.V.T.); University of Toronto, Toronto, Ontario, Canada (D.T.K., P.C.A., J.V.T., D.S.L., D.A.A.); Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada (D.S.L.); The Cardiac and Secondary Prevention Program, Toronto Rehabilitation Institute, Toronto, Ontario, Canada (D.A.A.); and Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada (D.A.A.). dennis.ko@ices.on.ca. 2. From the Institute of Clinical Evaluative Sciences, Toronto, Ontario, Canada (D.T.K., P.C.A., J.V.T., D.S.L., L.Y., D.A.A.); Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (D.T.K., J.V.T.); University of Toronto, Toronto, Ontario, Canada (D.T.K., P.C.A., J.V.T., D.S.L., D.A.A.); Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada (D.S.L.); The Cardiac and Secondary Prevention Program, Toronto Rehabilitation Institute, Toronto, Ontario, Canada (D.A.A.); and Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada (D.A.A.).
Abstract
BACKGROUND: Higher-risk patients may not receive evidence-based therapy because of limited life expectancy, which is a composite measure that encompasses many patient factors, including age, frailty, and comorbidities. In this study, we evaluated the extent to which treatment care gaps can be explained by a difference in projected life expectancy. METHODS AND RESULTS: An observational cohort study was conducted on acute myocardial infarction patients hospitalized in Ontario, Canada. Projected life expectancy was estimated using actual survival data with extrapolation using proportional hazard models adjusting for important covariates. The relationship between projected life expectancy with statins and reperfusion therapy was examined using generalized linear models. Among the 7001 acute myocardial infarction patients, 84.3% were prescribed statins and 72.9% were treated with reperfusion therapy. When projected life expectancy was <10 years, the likelihood of receiving either treatment declined progressively with reduction in life expectancy (P<0.001). At the 25th percentile of projected life expectancies, the likelihood of receiving a statin decreased by 1.4% (95% confidence interval, 1.0-1.8%), and acute reperfusion therapy decreased by 2.6% (95% confidence interval, 1.8-3.3%) for each year decline in projected life expectancy. CONCLUSIONS:Life expectancy of a patient strongly influences evidence-based treatment in acute myocardial infarction. It was seen not only among patients with limited life expectancies but also among those with many years to live. Treatment care gaps may reflect clinicians' synthesis about frailty and life-expectancy gains.
RCT Entities:
BACKGROUND: Higher-risk patients may not receive evidence-based therapy because of limited life expectancy, which is a composite measure that encompasses many patient factors, including age, frailty, and comorbidities. In this study, we evaluated the extent to which treatment care gaps can be explained by a difference in projected life expectancy. METHODS AND RESULTS: An observational cohort study was conducted on acute myocardial infarctionpatients hospitalized in Ontario, Canada. Projected life expectancy was estimated using actual survival data with extrapolation using proportional hazard models adjusting for important covariates. The relationship between projected life expectancy with statins and reperfusion therapy was examined using generalized linear models. Among the 7001 acute myocardial infarctionpatients, 84.3% were prescribed statins and 72.9% were treated with reperfusion therapy. When projected life expectancy was <10 years, the likelihood of receiving either treatment declined progressively with reduction in life expectancy (P<0.001). At the 25th percentile of projected life expectancies, the likelihood of receiving a statin decreased by 1.4% (95% confidence interval, 1.0-1.8%), and acute reperfusion therapy decreased by 2.6% (95% confidence interval, 1.8-3.3%) for each year decline in projected life expectancy. CONCLUSIONS: Life expectancy of a patient strongly influences evidence-based treatment in acute myocardial infarction. It was seen not only among patients with limited life expectancies but also among those with many years to live. Treatment care gaps may reflect clinicians' synthesis about frailty and life-expectancy gains.
Authors: Alberto Pilotto; Pietro Gallina; Francesco Panza; Massimiliano Copetti; Alberto Cella; Alfonso Cruz-Jentoft; Julia Daragjati; Luigi Ferrucci; Stefania Maggi; Francesco Mattace-Raso; Marc Paccalin; Maria Cristina Polidori; Eva Topinkova; Gianluca Trifirò; Anna-Karin Welmer; Timo Strandberg; Niccolò Marchionni Journal: Am J Cardiol Date: 2016-08-30 Impact factor: 2.778
Authors: Mark G O'Doherty; Karen Cairns; Vikki O'Neill; Felicity Lamrock; Torben Jørgensen; Hermann Brenner; Ben Schöttker; Tom Wilsgaard; Galatios Siganos; Kari Kuulasmaa; Paolo Boffetta; Antonia Trichopoulou; Frank Kee Journal: Eur J Epidemiol Date: 2016-01-18 Impact factor: 8.082
Authors: Peter Cram; Laura A Hatfield; Pieter Bakx; Amitava Banerjee; Christina Fu; Michal Gordon; Renaud Heine; Nicole Huang; Dennis Ko; Lisa M Lix; Victor Novack; Laura Pasea; Feng Qiu; Therese A Stukel; Carin Uyl de Groot; Lin Yan; Bruce Landon Journal: BMJ Date: 2022-05-04